[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"LG Chem\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":241},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,51,76,101,129,160,184,207],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100650768","phase-1-a-study-of-lg00313112-in-participants-with-advanced-solid-malignancies-harboring-a-tp53-y220c-mutation-100650768",false,"NCT07752875","A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation","A Phase 1\u002F2, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation","Inclusion Criteria:\n\n1. Males and females aged 18 years or older\n2. Diagnosed locally advanced unresectable or metastatic solid tumor with a TP53 Y220C mutation.\n3. Documented disease progression during or after the most recent line of therapy. In addition, must be refractory to or intolerant of standard of care therapy or have no standard therapy.\n4. Measurable disease per RECIST v1.1.\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n6. Adequate organ function.\n\nExclusion Criteria:\n\n1. Investigational therapy or anti-cancer therapy within 21 days or 5 half-lives prior to the first dose of study drug.\n2. Radiotherapy within 14 days prior to the first dose of study drug.\n3. Known brain metastases (Exception: Brain metastases are permitted if the participant is neurologically stable), leptomeningeal disease or carcinomatous meningitis.\n4. Uncontrolled pleural effusion, pericardial effusion, or ascites.\n5. History of myocardial infarction or unstable angina within 6 months prior to enrollment, or clinically significant cardiac disease\n6. Serious infections requiring intravenous antibiotics within 14 days of first dose of study drug.\n7. Active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection\n8. Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease\n9. History of prior organ transplant\n10. Currently receiving strong Cytochrome P4503A (CYP3A4) inhibitors or inducers","ALL","18 Years",{"count":19,"type":20},250,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This is a first-in-human, Phase 1\u002F2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C mutation",[27,28,29,30,31,32,33,34,35,36],"Ovarian Cancer","Small Cell Lung Cancer","Non Small Cell Lung Cancer","Colorectal Cancer","Esophageal Cancer","Breast Cancer","Endometrial Cancer","Head and Neck Cancer","Pancreatic Cancer","Locally Advanced Unresectable or Metastatic Solid Tumor",[38],"Solid Tumor, TP53 Y220C Mutation","NOT_YET_RECRUITING","2026-08-03",{"date":42,"type":43},"2026-08-07","ACTUAL",{"date":45,"type":20},"2026-12-01",{"date":47,"type":20},"2033-04-30",{"name":49,"class":50},"LG Chem","INDUSTRY",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100647576","phase-4-a-study-of-leuprorelin-1-month-4-week-formulation-in-children-with-central-precocious-puberty-100647576","NCT07710430","A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty","A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children With Central Precocious Puberty","Inclusion Criteria:\n\n1. Tanner stage =\\>2\n2. Girls younger than 9 years old, boys younger than 10 years old\n3. Subjects who are diagnosed with central precocious puberty (CPP)\n\nExclusion Criteria:\n\n1. GnRH-independent precocious puberty, incomplete precocious puberty, progressive brain tumors, pituitary adenoma\n2. Hepatic impairment or abnormal liver function tests at screening\n3. Renal impairment or abnormal renal function at screening\n4. Use of following within 8 weeks prior to screening or during the study: medications affecting gonadotropin or sex hormone, systemic steroids, herbal medications\n5. Use of medications associated with seizures\n6. Requirement for treatments affecting the hypothalamic-pituitary-gonadal axis\n7. History of seizures, epilepsy, cerebrovascular disease, or central nervous system disorders\u002Ftumors\n8. Known or suspected malignancy","10 Years",{"count":60,"type":20},43,[62],"PHASE4","A Single-Arm, Open-Label, Multicenter, Prospective Clinical Study to Evaluate the Effectiveness and Safety of Leuprorelin 1-Month (4-Week) Formulation Administered for 24 Months in Children with Central Precocious Puberty",[65],"Central Precocious Puberty","RECRUITING","2026-07-28",{"date":69,"type":43},"2026-07-29",{"date":71,"type":20},"2026-08-01",{"date":73,"type":20},"2030-04-30",{"name":49,"class":50},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":75},"100623454","phase-1-the-food-effect-on-pharmacokinetics-of-fixed-dose-combination-of-gemigliptindapagliflozinmetformin-in-healthy-volunteers-100623454","NCT07396844","The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin\u002FDapagliflozin\u002FMetformin in Healthy Volunteers","A Single Dose, Randomized, Open-label, Two-way Crossover Food-effect Bioavailbility Study of Fixed Dose Combination of Gemigliptin\u002FDapagliflozin\u002FMetformin 50\u002F10\u002F1000 mg Sustained Release Tablets Under Fasting and Fed Conditions in Healthy Volunteers","Inclusion Criteria:\n\n1. Healthy Thai male and female subjects between the ages of 18 to 55 years.\n2. Body mass index between 18.5 to 30.0 kg\u002Fm2.\n3. Normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening.\n4. Non-pregnant woman and not currently breast feeding.\n5. Female subjects abstain from either hormonal method of contraception or hormone replacement therapy.\n6. Male subjects who are willing or able to use effective contraceptive.\n7. Have voluntarily given written informed consent by the subject prior to participating in this study.\n\nExclusion Criteria:\n\n1. History of allergic reaction or hypersensitivity to gemigliptin or dapagliflozin or metformin.\n2. History of evidence of clinically significant renal, hepatic, gastrointestinal, hematological, endocrine, pulmonary or respiratory, cardiovascular, neurologic, allergic disease, or any significant ongoing chronic medical illness.\n3. History of evidence of diabetic ketoacidosis.\n4. History of evidence of genital infections, urinary tract infections within 14 days prior to check-in.\n5. Have a eGFR (CKD-EPI) \\\u003C 60 mL\u002Fmin\u002F1.73 m2.\n6. History or evidence of alcoholism or harmful use of alcohol within 2 years prior to screening.\n7. Participated in other clinical trial within 90 days prior to check-in.",true,"55 Years",{"count":86,"type":20},28,[23],"This is a single dose, randomized, open-label, two-way crossover study to investigate the food-effect bioavailability of the fixed-dose combination of Gemigliptin\u002FDapagliflozin\u002FMetformin 50\u002F10\u002F1000 mg in healthy volunteers under fasting and fed conditions.",[90,91,92],"Healthy","Fasting","Fed","2026-04-08",{"date":95,"type":43},"2026-04-13",{"date":97,"type":20},"2026-07-01",{"date":99,"type":20},"2026-07-31",{"name":49,"class":50},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":111,"briefSummary":112,"conditions":113,"keywords":119,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":75},"100541660","phase-1-study-to-evaluate-lb-lr1109-administered-alone-for-the-treatment-of-solid-tumor-and-in-combination-with-atezolizumab-for-the-treatment-of-nsclc-100541660","NCT06332755","Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC","A Phase 1a\u002F1b, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109, When Administered Alone for the Treatment of Advanced or Metastatic Solid Tumors, and in Combination With Atezolizumab for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)","LB-LR1109","Key Inclusion Criteria:\n\n1. Age ≥18 years old at the time of signing the ICF.\n2. (Phase 1a only) Participants must have 1 of the following histologically confirmed advanced or metastatic solid tumors with measurable or non-measurable disease as determined by RECIST v1.1,\n\n   \\- NSCLC, HNSCC, RCC, urothelial carcinoma, or malignant melanoma.\n3. (Phase 1a only) Participants who have metastatic disease which has progressed during or after approved standard therapies or are intolerant to approved therapies, or for which the participant refuses or is ineligible for standard therapy.\n4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1.\n5. Life expectancy ≥12 weeks.\n6. Participants with adequate organ function\n7. No potential for childbearing or agree to use adequate contraception\n8. Ability to understand the study purpose and procedures and have the willingness to sign a written informed consent document.\n9. (Phase 1b only ) Must have histologically confirmed advanced or metastatic NSCLC without actionable genomic alteration that have approved therapies in the location where the participant's live and with measurable disease as determined by RECIST v1.1\n\nKey Exclusion Criteria:\n\n1. Clinically significant cardiac disease or cardiac failure.\n2. Untreated or unstable brain or central nervous system (CNS) metastases or Leptomeningeal disease\n3. Participants with any concurrent active malignancies\n4. Has received prior therapy targeting LILRB or immunoglobulin-like transcript pathway.\n5. History of life-threatening toxicity related to prior immune therapy\n6. Has not recovered to ≤ Grade 1 or baseline from AEs and\u002For complications from prior surgical intervention or any anti-cancer treatment before starting study treatment\n7. Participants must not have an active, known, or suspected autoimmune disease.\n8. Evidence of active infection requiring IV antibiotic treatment ≤7 days prior to initiation of study treatment therapy (does not apply to viral infections that are presumed to be associated with the underlying tumor type required for study entry).\n9. Pregnant or lactating or expecting to conceive a child during the study or within 6 months after the last dose of study intervention.\n10. Any condition that would, in the Investigator's judgment, interfere with full participation in the study, including administration of study intervention and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.\n11. (Phase 1b only) Participants who were previously exposed to atezolizumab",{"count":110,"type":20},76,[23],"This is a Phase 1a\u002F1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)\u002FRecommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109 as monotherapy in participants with advanced and\u002For metastatic non small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma, or malignant melanoma and no available standard of care treatment options, and as combination therapy with atezolizumab in participants with advanced and\u002For metastatic NSCLC.",[114,115,116,117,118],"Non-small Cell Lung Cancer(NSCLC)","Head and Neck Squamous Cell Carcinoma(HNSCC)","Renal Cell Carcinoma(RCC)","Urothelial Carcinoma","Malignant Melanoma",[120],"solid tumor","2025-11-19",{"date":123,"type":43},"2025-11-24",{"date":125,"type":43},"2024-06-05",{"date":127,"type":20},"2028-03",{"name":49,"class":50},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":83,"sex":16,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":140,"briefSummary":142,"conditions":143,"keywords":150,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":75},"100588906","phase-2-a-phase-iiiii-study-to-evaluate-the-immunogenicity-safety-and-lot-to-lot-consistency-of-lbvd-a-fully-liquid-hexavalent-diphtheria-tetanus-whole-cell-pertussis-hepatitis-b-poliovirus-haemophilus-influenzae-type-b-conjugate-dtwp-hepb-ipv-hib-vaccine-in-healthy-infants-as-primary-series-100588906","NCT06947499","A Phase II\u002FIII Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series","A Prospective, Multi-national, Multi-center, Open-label, Randomized, Active Controlled, Parallel Group, Operationally Seamless Phase II\u002FIII Clinical Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus (Inactivated)-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, Compared to Co-administration of DTwP-HepB-Hib Vaccine and IPV Vaccine in Healthy Infants at 6-, 10-, and 14-week of Age as Primary Series","Inclusion Criteria:\n\n* healthy infants from 6 weeks to 8 weeks of age (both inclusive)\n* body weight ≥ 3.2 kg\n* born at full term pregnancy (≥ 37 weeks)\n* signed informed consent by parent(s) or legally acceptable representative(s)\n\nExclusion Criteria:\n\n* Known history of Hib infection, HepB, diphtheria, tetanus, pertussis, or poliomyelitis\n* Household contact or intimate exposure with a confirmed case of Hib, HepB, diphtheria, pertussis, tetanus or poliomyelitis within 30 days prior to study registration\n* Known history of SARS-CoV-2 infection\n* Participant's mother is HepB antigen or HIV positive\n* Fever ≥ 38.0 C\u002F100.4 F within 3 days prior to enrollment\n* Vaccination history of non-study vaccines within 30 days prior to enrollment except for pneumococcal conjugate, rotavirus, HepB and Bacillus Calmette Guerin (BCG)\n* Previous use of any diphtheria, tetanus, pertussis-based combination vaccine(s), Hib conjugate, poliovirus, or combination\n* Received immunosuppressive agents or other immune-modifying drugs\n* Previous use of blood or blood-derived products\n* Any history of allergy (hypersensitivity) to any of the vaccine components\n* Participation in another interventional clinical trial within 4 weeks of expected first vaccination","6 Weeks","8 Weeks",{"count":139,"type":20},1186,[24,141],"PHASE3","The purpose of this study is to evaluate immunogenicity, safety and lot-to-lot consistency of LBVD in comparison to co-administration of Pentavalent vaccine and Poliomyelitis Vaccine (Inactivated) in separate injections at four weeks after completion of three-dose primary series at 6-10-14 weeks of age when administered to healthy infants",[144,145,146,147,148,149],"Diphtheria","Tetanus","Pertussis","Hepatitis B","Poliomyelitis","Haemophilus Influenzae Type b",[151],"vaccination","2025-06-30",{"date":154,"type":43},"2025-07-03",{"date":156,"type":43},"2025-05-30",{"date":158,"type":20},"2027-04",{"name":49,"class":50},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":167,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":21,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":75},"100586900","phase-4-phase-iv-study-to-evaluate-the-efficacy-and-safety-of-fang-le-shu-compared-to-guo-na-fen-for-controlled-ovarian-stimulation-in-infertile-women-undergoing-in-vitro-fertilization-embryo-transfer-ivf-et-100586900","NCT06921395","Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulation in Infertile Women Undergoing in Vitro Fertilization-embryo Transfer (IVF-ET).","A Phase IV, Prospective, Randomized, Open-label, Active-controlled, Parallel-group, Multicenter Study to Evaluate Efficacy and Safety of Fang Le Shu (Recombinant FSH) Versus Guo Na Fen Used for Controlled Ovarian Stimulation in Infertile Women Undergoing In Vitro Fertilization-Embryo Transfer.","Inclusion Criteria:\n\n* Is pre-menopausal female aged ≥20 to \\\u003C40 years.\n* Has regular menstrual cycles of ≥25 to ≤35 days.\n* Has Normal baseline serum FSH, LH, E2, P4.\n* Is able to voluntarily sign the informed consent form (ICF).\n* Has history of infertility for at least 1 year before the day of randomization; however, subjects with confirmed diagnosis of infertility are eligible without fulfilling the 1-year requirement.\n\nExclusion Criteria:\n\n* Has any known clinically significant major systemic disease, or endocrine or metabolic abnormalities with the exception of controlled thyroid function disease.\n* Has body mass index (BMI) of \\>30 kg\u002Fm2.\n* Has clinically significant abnormalities of the uterus, ovary, or appendix prior to the day of randomization\n* Has history of surgeries that may affect oocyte retrieval or pregnancy outcome, such as surgical resection of uterine mediastinum, fibroids, or cysts (however, patients who received polypectomy are allowed to enroll).\n* Has history of severe ovarian hyperstimulation syndrome (OHSS) defined as Grade 4 or higher.\n* Poor ovarian reponder according to Bologna criteria\n* Has plans to donate oocyte or recieve embryo from another women or undergo preimplantation genetic testing(PGT)\n* Has history of three or more failures in previous IVF cycles\n* Has history of recurrent miscarriage\n* Has known current active pelvic inflammatory disease.\n* Is currently breastfeeding.\n* Has a contraindication to pregnancy that would preclude participation in the trial.","FEMALE","20 Years","39 Years",{"count":171,"type":20},248,[62],"The aim of this randomized, open-label, active-controlled, parallel-group, multicenter, phase IV study is to assess the efficacy and safety of Fang Le Shu versus Guo Na Fen used for controlled ovarian stimulation in infertile women undergoing In Vitro Fertilization-Embryo Transfer.",[175],"Female Infertility","2025-04-08",{"date":178,"type":43},"2025-04-10",{"date":180,"type":43},"2025-02-15",{"date":182,"type":20},"2026-06-30",{"name":49,"class":50},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":83,"sex":16,"minAge":191,"maxAge":192,"enrollmentInfo":193,"targetDuration":4,"studyType":21,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":4},"100563594","phase-2-study-to-evaluate-the-immunogenicity-of-lr20062-compared-to-control-when-administered-intramuscularly-in-healthy-infants-at-2-4-6-months-of-age-100563594","NCT06618196","Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age","A Phase II, Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter Study to Evaluate the Immunogenicity and Safety of DTaP-HepB-IPV-Hib Hexavalent Vaccine LR20062 Versus Hexaxim Administered Intramuscularly in Healthy Infants As Primary Series At 2, 4, 6 Months of Age","Inclusion Criteria:\n\n1. Is male or female aged two months (50 to 70 days inclusive) on the day of the first dose of study vaccine.\n2. Is born at full term of pregnancy (≥37 weeks of gestation) with a birth weight of ≥2.5 kg.\n\nExclusion Criteria:\n\nMedical conditions:\n\n1. Has a history of diphtheria, tetanus, pertussis, poliovirus, Hep B, or Hib infection.\n2. Has a known SARS-CoV-2 infection at Screening.\n3. Was born to a mother with a known history of Hep B infection based on HBsAg seropositivity.\n4. Was born to a mother with a known history of HIV infection based on HIV antibody seropositivity.\n5. Had a recent febrile illness, defined as axillary temperature ≥38.0℃ \\[≥100.4℉\\] occurring at or within 72 hours prior to receipt of study vaccine.\n\n   Prior\u002Fconcomitant therapy:\n6. Has previously received vaccination against diphtheria, tetanus, pertussis, poliovirus, and\u002For Hib infections since birth.\n7. Has received or is expected to receive immunosuppressive agents or other immune-modifying drugs during the conduct of the study.\n8. Meets one or more of the following systemic corticosteroid exclusion criteria:\n\n   1. Has received systemic corticosteroids (equivalent of ≥0.5 mg\u002Fkg total daily dose of prednisone) for ≥14 consecutive days and has not completed treatment at least 30 days prior to Screening.\n   2. Is expected to require any systemic corticosteroids during conduct of the study.\n\n   Note: Topical, ophthalmic, and inhaled steroids are permitted at the discretion of the Investigator.\n9. Has received any non-study vaccine within 30 days before the first dose of study vaccine or is scheduled to receive any other vaccine within one month after the third dose of study vaccine.\n\nException: Vaccines against BCG and Hep B at birth, rotavirus, MMR, and PCV if received according to the routine immunization schedule, and inactivated influenza vaccine, are allowed.","50 Days","70 Days",{"count":194,"type":20},336,[24],"This is a phase II, randomized, double-blind, active-controlled, parallel-group, multicenter study to evaluate the immunogenicity and safety of DTaP-HepB-IPV-Hib hexavalent vaccine LR20062 in healthy infants as primary series at 2, 4, 6 months of age.",[144,145,146,147,148,198],"Haemophilus Influenzae Type B Infection","2024-09-26",{"date":201,"type":43},"2024-10-01",{"date":203,"type":20},"2024-10-02",{"date":205,"type":20},"2026-04-30",{"name":49,"class":50},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":213,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":215,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":218,"phases":4,"briefSummary":219,"conditions":220,"keywords":226,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":75},"100178992","long-term-safety-and-effectiveness-of-growth-hormone-with-ghd-ts-crf-sga--iss-and-pws-in-children-100178992","NCT01604395","Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children","An Open, Multi-center, Prospective and Retrospective Observational Study to Evaluate the Long-term Safety and Effectiveness of Growth Hormone (Eutropin Inj. \u002F Eutropin Plus Inj.) Treatment With GHD, TS, CRF, SGA, ISS and PWS in Children","LGS","Inclusion Criteria:\n\n* short stature children aged 2 years or more\n* children with GHD,TS, CRF, SGA or ISS\n* written informed consent from the person, person's parent or legal guardian","2 Years",{"count":217,"type":20},6000,"OBSERVATIONAL","The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj.\u002FEutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).",[221,222,223,224,225],"Growth Hormone Deficiency","Turner Syndrome","Chronic Renal Failure","Small for Gestational Age","Idiopathic Short Stature",[227,228,229,230,231,232],"GHD","TS","CRF","SGA","ISS","PWS","2021-02-17",{"date":235,"type":43},"2021-02-21",{"date":237,"type":4},"2012-01",{"date":239,"type":20},"2032-12-31",{"name":49,"class":50},""]